Use of ADNF polypeptides for treating peripheral neurotoxicity

Details Use of ADNF polypeptides for treating peripheral neurotoxicity Use of ADNF polypeptides for treating peripheral neurotoxicity

2006-03-23

2008-11-18

Russel, Jeffrey E (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S013800, C514S014800, C514S015800, C514S016700, C514S021800

Reexamination Certificate

active

07452867

ABSTRACT:
This invention relates to the use of ADNF polypeptides in the treatment of neurotoxicity induced by chemical agents or by disease processes. The ADNF polypeptides include ADNF I and ADNF III (also referred to as ADNP) polypeptides, analogs, subsequences such as NAP and SAL, and D-amino acid versions (either wholly D-amino acid peptides or mixed D- and L-amino acid peptides), and combinations thereof which contain their respective active core sites.

REFERENCES:
patent: 4587046 (1986-05-01), Goodman et al.
patent: 5198420 (1993-03-01), Donahoe et al.
patent: 5556757 (1996-09-01), Alstyne et al.
patent: 5767240 (1998-06-01), Brenneman et al.
patent: 6113947 (2000-09-01), Cleland et al.
patent: 6174862 (2001-01-01), Brenneman
patent: 6613740 (2003-09-01), Gozes et al.
patent: 6933277 (2005-08-01), Brenneman et al.
patent: 2002/0111301 (2002-08-01), Brenneman et al.
patent: 2003/0166544 (2003-09-01), Clark et al.
patent: 2004/0053313 (2004-03-01), Gozes et al.
patent: 1 206 489 (2004-05-01), None
patent: WO 92/18140 (1992-10-01), None
patent: WO 96/11948 (1996-04-01), None
patent: WO 98/35042 (1998-08-01), None
patent: WO 00/27875 (2000-05-01), None
patent: WO 00/53217 (2000-09-01), None
patent: WO 01/12654 (2001-02-01), None
patent: WO 01/92333 (2001-12-01), None
patent: WO 2004/080957 (2004-09-01), None
Hausheer et al. “Diagnosis, Management, and Evaluation of Chemotherapy-Induced Peripheral Neuropathy,” Semin. Oncol., 2006, 33, 15-49.
Stillman & Cata “Management of chemotherapy-induced peripheral neuropathy,” Curr. Pain Headache Rep., 2006, 10, 279-87, abstract only.
Chiba, Tomohiro et al.; “Neuroprotective Effect of Activity-Dependent Neurotrophic Factor Against Toxicity From Familial Amyotrophic Lateral Sclerosis-Linked Mutant SOD1 in Vitro and in Vivo”; 2004,Journal of Neuroscience Research, vol. 78, pp. 542-552.
Bassan, M. et al. “VIP-Induced Mechanism of Neuroprotection: The Complete Sequence of a Femtomolar-Acting Activity-Dependent Neuroprotective Protein.”Regulatory Peptides, vol. 71, No. 2, (Aug. 15, 1997).
Bedikian, Agop Y., et al., “Phase II Trial of Docetaxel in Patients with Advanced Cutaneous Malignant Melanoma Previously Untreated with Chemotherapy;” Dec. 1995; Journal of Clinical Oncology; Vo. 13; No. 12; pp. 2895-2899.
Bassan, M. et al. “Complete Sequence of a Novel Protein Containing a Femtomolar-Activity-Dependent Neuroprotective Peptide.”Journal of Neurochemistry, vol. 72, pp. 1283-1293 (1999).
Beni-Adani, L. et al. “Activity-Dependent Neurotrophic Protein is Neuroprotective in a Mouse Model of Closed Head Injury.” Society for Neuroscience, 28thAnnual Meeting, Los Angeles, CA, Nov. 7-12, 1998.Abstracts, vol. 23, Part 1, p. 1043 (1998).
Brenneman, D.C. and Gozes, I. “A Femtomolar-Acting Neuroprotective Peptide.”Journal of Clinical Investigation, vol. 97, pp. 2299-2307 (1996).
Brenneman et al. “Neuronal Cell Killing by the Envelope Protein of HIV and Its Prevention by Vasoactive Intestinal Peptide.”Nature335:636 (1988).
Brenneman et al. “N-Methyl-D-Aspartate Receptors Influence Neuronal Survival in Developing Spinal Cord Cultures”Dev. Brain Res. 51:63 (1990).
Brenneman, D.E. et al. “Identification of a Nine Amino Acid Core Peptide from Activity Dependent Neurotrophic Factor I.” Society for Neuroscience, 27thAnnual Meeting, New Orleans, LA, Oct. 25-30, 1997.Abstracts, vol. 23, Part 2, p. 2250 (1997).
Brenneman, D.E. et al. “Activity-Dependent Neurotrophic Factor: Structure-Activity Relationships of Femtomolar-Acting Peptides.”Journal of Pharmacology and Experimental Therapeutics, vol. 285, pp. 619-627 (1998).
Brenneman, D.E., et al.; “Protective Peptides Derived from Novel Glial Proteins;” 2000; Biochemical Society Transactions; vol. 28; Part 4; pp. 452-455.
Chiba, Tomohiro, et al., “Development of a Femtomolar-Acting Humanin Derivative Named Colivelin by Attaching Activity-Dependent Neurotropic Factor to its N Terminus: Characterization of Colivelin-Mediated Neuroprotection against Alzheimer's Disease-Relevant Insults in Vitro and In Vivo;” Nov. 2, 2005;The Journal of Neuroscience; vol. 25; No. 44; pp. 10252-10261.
Davidson, A. et al. “Protection Against Developmental Retardation and Learning Impairments in Apolipoprotein E-Deficient Mice by Activity-Dependent Femtomolar-Acting Peptides.” Society for Neuroscience, 27thAnnual Meeting, New Orleans, LA, Oct. 25-30, 1997.Abstracts, vol. 23, Part 2, p. 2250 (1997).
Dibbern, D.A., Jr. et al. “Inhibition of Murine Embryonic Growth by Human Immunodeficiency Virus Envelope Protein and Its Prevention by Vasoactive Intestinal Peptide and Activity-Dependent Neurotrophic Factor.”Journal of Clinical Investigation, vol. 99, pp. 28377-2841 (1997).
Divinski, Inna, et al ., “A Femtomolar Acting Octapeptide Interacts with Tubulin and Protecots Astrocytes Against Zinc Intoxication;” The Journal of Biological Chemistry; Jul. 2, 2004; vol. 279, No. 27; pp. 28531-28538.
Furman, Sharon, et al.; “Subcellular Localization and Secretion of Activity-Dependent Neuroprotective Protein in Astrocytes;” 2004; Neuron Gilia Biology; vol. 1; pp. 193-199.
GenBank Accession No. AB018327 from the DNA Data Bank of Japan (DDBJ) (released Nov. 17, 1998).
Giladi, E. “Protection Against Developmental and Learning Impairments in Apolipoprotein E-Deficient Mice by Activity-Dependent Femtomolar-Acting Peptides.”Neuroscience Letters, Supplement 48 S1-S60, p. S19 (1997).
Glazner, G.W. et al. “A 9 Amino Acid Peptide Fragment of Activity-Dependent Neurotrophic Factor (ADNF) Protects Neurons from Oxidative Stress-Induced Death,” Society for Neuroscience, 27thAnnual Meeting, New Orleans, LA, Oct. 25-30, 1997.Abstracts, vol. 23, Part 2, p. 2249 (1997).
Glazner, G.W. et al. “Activity Dependent Neurotrophic Factor: A Potent Regulator of Embryonic Growth.”Anat. Embryol. 200:65-71 (1999).
Gozes, I. and Brenneman, D.E. “Activity-Dependent Neurotrophic Factor (ADNF).”Journal of Molecular Neuroscience, vol. 7, pp. 235-244 (1996).
Gozes, I. et al. “Stearyl-Norleucine-Vasoactive Intestinal Peptide (VIP): A novel VIP Analog for Noninvasive Impotence Treatment.”Endocrinology, vol. 134, pp. 2125 (1994).
Gozes, I. et al. “Superactive Lipophilic Peptides Discriminate Multiple Vasoactive intestinal Peptide Receptors.”Journal of Pharmacology and Experimental Therapeutics, vol. 273, pp. 161-167 (1995).
Gozes, I. et al. “Neuroprotective Strategy for Alzheimer Disease: Intranasal Administration of a Fatty Neuropeptide.”Proc. Natl. Acad. Sci. USA, vol. 93, pp. 427-432 (1996).
Gozes I. et al. “Antiserum to Activity-Dependent Neurotrophic Factor Produces Neuronal Cell Death in CNS Cultures: Immunological and Biological Specificity.”Developmental Brain Research, vol. 99, pp. 167-175 (1997).
Gozes, I. et al. A Femtomolar-Acting Activity-Dependent Neuroprotective Protein (ADNP).Neuroscience Letters, Supplement 48 S1-S60, p. S21 (1997).
Gozes, I. et al. “Protection Against Developmental Retardation in Apolipoprotein E-Deficient Mice by a Fatty neuropeptide: Implications for Early Treatment of Alzheimer's Disease.”Journal of Neurobiology, vol. 33, pp. 329-342 (1997).
Gozes, I. et al. “The cDNA Structure of a Novel Femtomolar-Acting Neuroprotective Protein: Activity-Dependent-Neurotrophic Factor III (ADNFIII).” Society for Neuroscience, 27thAnnual Meeting, New Orleans, LA, Oct. 25-30, 1997.Abstracts, vol. 23, Part 2, p. 2250 (1997).
Gozes, et al., “A Novel Signaling Molecule for Neuropeptide Action: Activity-dependent Neuroprotective Protein”; Annals of the New York Academy of Sciences, 897:125-135 (1999).
Gozes, I. et al. “Activity-dependent neurotrophic factor: Intranasal administration of femtomolar-acting peptides improve performance in a water maze”Journal of Pharmacol

Affiliated with

Also associated with

Rating

Use of ADNF polypeptides for treating peripheral neurotoxicity does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of ADNF polypeptides for treating peripheral neurotoxicity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of ADNF polypeptides for treating peripheral neurotoxicity will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4022515